227 related articles for article (PubMed ID: 24811890)
1. Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms.
Wheler JJ; Parker BA; Lee JJ; Atkins JT; Janku F; Tsimberidou AM; Zinner R; Subbiah V; Fu S; Schwab R; Moulder S; Valero V; Schwaederle M; Yelensky R; Miller VA; Stephens MP; Meric-Bernstam F; Kurzrock R
Oncotarget; 2014 May; 5(9):2349-54. PubMed ID: 24811890
[TBL] [Abstract][Full Text] [Related]
2. Genetic alterations and their association with clinicopathologic characteristics in advanced breast carcinomas: focusing on clinically actionable genetic alterations.
Freitag CE; Mei P; Wei L; Parwani AV; Li Z
Hum Pathol; 2020 Aug; 102():94-103. PubMed ID: 32445652
[TBL] [Abstract][Full Text] [Related]
3. Multiple gene aberrations and breast cancer: lessons from super-responders.
Wheler JJ; Atkins JT; Janku F; Moulder SL; Yelensky R; Stephens PJ; Kurzrock R
BMC Cancer; 2015 May; 15():442. PubMed ID: 26021831
[TBL] [Abstract][Full Text] [Related]
4. Nonamplification ERBB2 genomic alterations in 5605 cases of recurrent and metastatic breast cancer: An emerging opportunity for anti-HER2 targeted therapies.
Ross JS; Gay LM; Wang K; Ali SM; Chumsri S; Elvin JA; Bose R; Vergilio JA; Suh J; Yelensky R; Lipson D; Chmielecki J; Waintraub S; Leyland-Jones B; Miller VA; Stephens PJ
Cancer; 2016 Sep; 122(17):2654-62. PubMed ID: 27284958
[TBL] [Abstract][Full Text] [Related]
5. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive molecular profiling broadens treatment options for breast cancer patients.
Kawaji H; Kubo M; Yamashita N; Yamamoto H; Kai M; Kajihara A; Yamada M; Kurata K; Kaneshiro K; Harada Y; Hayashi S; Shimazaki A; Mori H; Akiyoshi S; Oki E; Oda Y; Baba E; Mori M; Nakamura M
Cancer Med; 2021 Jan; 10(2):529-539. PubMed ID: 33274848
[TBL] [Abstract][Full Text] [Related]
7. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing.
Janku F; Kaseb AO; Tsimberidou AM; Wolff RA; Kurzrock R
Oncotarget; 2014 May; 5(10):3012-22. PubMed ID: 24931142
[TBL] [Abstract][Full Text] [Related]
8. Characterizations of Cancer Gene Mutations in Chinese Metastatic Breast Cancer Patients.
Tao Z; Li T; Feng Z; Liu C; Shao Y; Zhu M; Gong C; Wang B; Cao J; Wang L; Du Y; Lizaso A; Li B; Zhang J; Hu X
Front Oncol; 2020; 10():1023. PubMed ID: 32695676
[No Abstract] [Full Text] [Related]
9. Genomic profiling of advanced-stage, metaplastic breast carcinoma by next-generation sequencing reveals frequent, targetable genomic abnormalities and potential new treatment options.
Ross JS; Badve S; Wang K; Sheehan CE; Boguniewicz AB; Otto GA; Yelensky R; Lipson D; Ali S; Morosini D; Chliemlecki J; Elvin JA; Miller VA; Stephens PJ
Arch Pathol Lab Med; 2015 May; 139(5):642-9. PubMed ID: 25927147
[TBL] [Abstract][Full Text] [Related]
10. Blood-Based Next-Generation Sequencing Analysis of Appendiceal Cancers.
Shaib WL; Zakka K; Staley C; Roberts A; Akce M; Wu C; Alese OB; El-Rayes BF
Oncologist; 2020 May; 25(5):414-421. PubMed ID: 31784493
[TBL] [Abstract][Full Text] [Related]
11. Somatic alterations of TP53, ERBB2, PIK3CA and CCND1 are associated with chemosensitivity for breast cancers.
Yang L; Ye F; Bao L; Zhou X; Wang Z; Hu P; Ouyang N; Li X; Shi Y; Chen G; Xia P; Chui M; Li W; Jia Y; Liu Y; Liu J; Ye J; Zhang Z; Bu H
Cancer Sci; 2019 Apr; 110(4):1389-1400. PubMed ID: 30776175
[TBL] [Abstract][Full Text] [Related]
12. Comparative genomic analysis of primary tumors and metastases in breast cancer.
Bertucci F; Finetti P; Guille A; Adélaïde J; Garnier S; Carbuccia N; Monneur A; Charafe-Jauffret E; Goncalves A; Viens P; Birnbaum D; Chaffanet M
Oncotarget; 2016 May; 7(19):27208-19. PubMed ID: 27028851
[TBL] [Abstract][Full Text] [Related]
13. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice.
Vasan N; Yelensky R; Wang K; Moulder S; Dzimitrowicz H; Avritscher R; Wang B; Wu Y; Cronin MT; Palmer G; Symmans WF; Miller VA; Stephens P; Pusztai L
Oncologist; 2014 May; 19(5):453-8. PubMed ID: 24710307
[TBL] [Abstract][Full Text] [Related]
14. Targeted next-generation sequencing enables reliable detection of HER2 (ERBB2) status in breast cancer and provides ancillary information of clinical relevance.
Pfarr N; Penzel R; Endris V; Lier C; Flechtenmacher C; Volckmar AL; Kirchner M; Budczies J; Leichsenring J; Herpel E; Noske A; Weichert W; Schneeweiss A; Schirmacher P; Sinn HP; Stenzinger A
Genes Chromosomes Cancer; 2017 Apr; 56(4):255-265. PubMed ID: 27792260
[TBL] [Abstract][Full Text] [Related]
15. Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities.
Craig DW; O'Shaughnessy JA; Kiefer JA; Aldrich J; Sinari S; Moses TM; Wong S; Dinh J; Christoforides A; Blum JL; Aitelli CL; Osborne CR; Izatt T; Kurdoglu A; Baker A; Koeman J; Barbacioru C; Sakarya O; De La Vega FM; Siddiqui A; Hoang L; Billings PR; Salhia B; Tolcher AW; Trent JM; Mousses S; Von Hoff D; Carpten JD
Mol Cancer Ther; 2013 Jan; 12(1):104-16. PubMed ID: 23171949
[TBL] [Abstract][Full Text] [Related]
16. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
[TBL] [Abstract][Full Text] [Related]
17. Mutational Diversity and Therapy Response in Breast Cancer: A Sequencing Analysis in the Neoadjuvant GeparSepto Trial.
Loibl S; Treue D; Budczies J; Weber K; Stenzinger A; Schmitt WD; Weichert W; Jank P; Furlanetto J; Klauschen F; Karn T; Pfarr N; von Minckwitz G; Möbs M; Jackisch C; Sers C; Schneeweiss A; Fasching PA; Schem C; Hummel M; van Mackelenbergh M; Nekljudova V; Untch M; Denkert C
Clin Cancer Res; 2019 Jul; 25(13):3986-3995. PubMed ID: 30979740
[TBL] [Abstract][Full Text] [Related]
18. Genomic landscape of salivary gland tumors.
Kato S; Elkin SK; Schwaederle M; Tomson BN; Helsten T; Carter JL; Kurzrock R
Oncotarget; 2015 Sep; 6(28):25631-45. PubMed ID: 26247885
[TBL] [Abstract][Full Text] [Related]
19. Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients.
Hempel D; Ebner F; Garg A; Trepotec Z; Both A; Stein W; Gaumann A; Güttler L; Janni W; DeGregorio A; Hempel L; Milani V
Sci Rep; 2020 Jun; 10(1):10459. PubMed ID: 32591580
[TBL] [Abstract][Full Text] [Related]
20. Profiling the Somatic Mutational Landscape of Breast Tumors from Hispanic/Latina Women Reveals Conserved and Unique Characteristics.
Ding YC; Song H; Adamson AW; Schmolze D; Hu D; Huntsman S; Steele L; Patrick CS; Tao S; Hernandez N; Adams CD; Fejerman L; Gardner K; Nápoles AM; Pérez-Stable EJ; Weitzel JN; Bengtsson H; Huang FW; Neuhausen SL; Ziv E
Cancer Res; 2023 Aug; 83(15):2600-2613. PubMed ID: 37145128
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
